- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04526496
Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers
February 8, 2021 updated by: Sichuan Haisco Pharmaceutical Group Co., Ltd
A 2-part, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of FTP-198 in Healthy Volunteers
This is a first-in-human, Phase I, single-dose escalation and multiple-dose escalation clinical trial for FTP-198 conducted in Australian healthy volunteers.
The safety, tolerability, and pharmacokinetics of FTP-198 suspension in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Adelaide, Australia
- CMAX Clinical Research Pty Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects;
- Adult males and females, 18 to 55 years of age (inclusive) at screening;
- Body mass index ≥ 18.0 and ≤ 30.0 kg/m2, with a body weight ≥ 50 kg at screening;
- Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 1 month prior to first study drug administration;
Medically healthy without clinically significant abnormalities at screening and predose on Day 1, including:
- Physical examination without any clinically relevant findings;
- Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood pressure in the range of 50 to 95 mmHg after 5 minutes in supine position;
- Heart rate in the range of 50 to 100 bpm after 5 minutes rest in supine position;
- Body temperature, between 35.0°C and 37.5°C;
- No clinically significant findings in serum chemistry, hematology, coagulation and urinalysis tests as judged by the investigator;
Conventional 12-lead ECG recording in triplicate (the mean of triplicate measurements will be used to determine eligibility at screening and predose on Day 1) consistent with normal cardiac conduction and function, including:
- Normal sinus rhythm with HR between 50 and 100 bpm, inclusive;
- QT interval corrected using the Fridericia method (QTcF) between 350 to 450 msec for male subjects and 350 to 470 msec for female subjects, inclusive;
- QRS duration of < 120 msec;
- PR interval of ≤ 210 msec;
- Electrocardiogram morphology consistent with healthy cardiac ventricular conduction and normal rhythm, and with measurement of the QT interval;
- No family history of short or long QT syndrome;
- No history of risk factors for torsade de pointes or the diagnosis;
Female participants must:
- Be of nonchildbearing potential ie, surgically sterilized (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before screening) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause), or
- If of childbearing potential, must have a negative pregnancy test at screening (blood test) and before the first study drug administration (Day -1 urine test). They must agree not to attempt to become pregnant, must not donate ova, and must use a highly effective contraceptive method from signing the consent form until at least 30 days after the last dose of study drug.
- Male participants, if not surgically sterilized, must be willing not to donate sperm and, if engaging in sexual intercourse with a female partner who could become pregnant, must be willing to use a condom in addition to having the female partner use a highly effective contraceptive method from signing the consent form until at least 90 days after the last dose of study drug;
- Have suitable venous access for blood sampling;
- Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
Exclusion Criteria:
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the PI to be clinically relevant;
- Current infection that requires antibiotic, antifungal, antiparasitic or antiviral medications;
- Any history of malignant disease in the last 10 years (excludes surgically resected skin squamous cell or basal cell carcinoma);
- Presence of clinically relevant immunosuppression from, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia;
- Use of or plans to use systemic immunosuppressive (eg, corticosteroids, methotrexate, azathioprine, cyclosporine) or immunomodulating medications (eg, interferon) during the study or within 4 months prior to the first study drug administration;
- Liver function test results (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT], and gammaglutamyl transferase [GGT]) and total bilirubin must not be elevated more than 1.2-fold above the upper limit of normal (ULN);
- Positive test results for active human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies (Abs);
- History of active, latent or inadequately treated tuberculosis infection;
- Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs;
- Estimated creatinine clearance (CrCl) < 40 mL/min using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN;
- History of substance abuse or alcohol abuse within 12 months prior to first study drug administration;
- Positive drug or alcohol test results;
- Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol;
- Demonstrated clinically significant (required intervention, eg, emergency room visit, epinephrine administration) allergic reactions (eg, food, drug, or atopic reactions, asthmatic episodes) which, in the opinion of the investigator, would interfere with the volunteer's ability to participate in the trial;
- Known hypersensitivity to any of the study drug ingredients;
- Use of any live vaccinations within 30 days prior to the first study drug administration except for the influenza vaccine;
- For women of childbearing potential, a positive serum pregnancy test at screening or a positive urine pregnancy test with confirmatory serum pregnancy test on Day -1;
- Donation of blood or plasma within 30 days prior to first study drug administration, or loss of whole blood of more than 500 mL within 30 days prior to randomization, or receipt of a blood transfusion within 1 year of first study drug administration;
- Participation in another investigational clinical trial within 60 days prior to the first study drug administration;
- Any other condition or prior therapy that in the opinion of the PI would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements;
- Is an employee of an investigator or sponsor or an immediate relative of an investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single Ascending Doses
50mg-600mg
|
Single dose of FTP-198, 6 dose levels, oral suspension
Placebo matched to FTP-198, oral suspension
|
EXPERIMENTAL: Multiple Ascending Doses
dose to be determined
|
Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days
Placebo matched to FTP-198, oral suspension, 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number and severity of treatment emergent adverse events (TEAEs)
Time Frame: 7 days after the last doses
|
To assess the safety and tolerability of single and multiple ascending oral doses of FTP-198 in healthy Australian subjects
|
7 days after the last doses
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The level of changes of pharmacodynamic biomarkers
Time Frame: within 0.5 hours before administration until 24 hours (single dose) or 48 hours (multiple doses) after administration
|
The change-from-baseline values of plasma lysophosphatidic acid (LPA) as PD biomarkers
|
within 0.5 hours before administration until 24 hours (single dose) or 48 hours (multiple doses) after administration
|
Cmax
Time Frame: within 0.5 hours before administration until 48 hours after administration
|
peak palsma concentration
|
within 0.5 hours before administration until 48 hours after administration
|
AUC
Time Frame: within 0.5 hours before administration until 48 hours after administration
|
area under the plasma concentration versus time curve
|
within 0.5 hours before administration until 48 hours after administration
|
t1/2
Time Frame: within 0.5 hours before administration until 48 hours after administration
|
half-life
|
within 0.5 hours before administration until 48 hours after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 24, 2020
Primary Completion (ACTUAL)
November 5, 2020
Study Completion (ACTUAL)
November 5, 2020
Study Registration Dates
First Submitted
March 9, 2020
First Submitted That Met QC Criteria
August 21, 2020
First Posted (ACTUAL)
August 25, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 9, 2021
Last Update Submitted That Met QC Criteria
February 8, 2021
Last Verified
March 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- FTP198-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on FTP-198, single dose
-
Taiho Pharmaceutical Co., Ltd.CompletedStress Urinary IncontinenceJapan
-
AblynxCompletedHealthy VolunteersUnited States
-
PfizerCompleted
-
Galapagos NVCompleted
-
Bridge Biotherapeutics, Inc.KCRN Research, LLCCompletedHealthy ParticipantsUnited States
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Waterstone Pharmaceutical (Wuhan) Co., LTD.Completed
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina